Ilyang Pharmaceutical Co.,Ltd (KRX:007570)
South Korea · Delayed Price · Currency is KRW 11,400
+220 (1.97%)
At close: Apr 2, 2026
KRX:007570 Revenue
In the year 2025, Ilyang Pharmaceutical Co.,Ltd had annual revenue of 272.42B KRW with 1.39% growth. Ilyang Pharmaceutical Co.,Ltd had revenue of 78.91B in the quarter ending December 31, 2025, a decrease of -4.23%.
Revenue
272.42B
Revenue Growth
+1.39%
P/S Ratio
0.75
Revenue / Employee
409.04M
Employees
666
Market Cap
204.34B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 272.42B | 3.74B | 1.39% |
| Dec 31, 2024 | 268.68B | 2.01B | 0.75% |
| Dec 31, 2023 | 266.67B | 18.90B | 7.63% |
| Dec 31, 2022 | 247.77B | 5.26B | 2.17% |
| Dec 31, 2021 | 242.51B | -100.82B | -29.36% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chong Kun Dang Holdings | 959.01B |
| Suheung | 722.31B |
| Daewon Pharmaceutical | 590.70B |
| Jeil Pharmaceutical Co.,Ltd | 567.24B |
| Samjin Pharmaceuticals | 274.03B |
| Kyongbo Pharmaceutical | 264.10B |
| JW Lifescience | 257.83B |
| Whan In Pharm | 255.21B |